Institute for Global Health


BESTT Women's Study: Bone Evaluation in HIV-positive women who switch from Truvada/NNRTI to Triumeq

Project Summary 

Treatment of HIV has been revolutionised by successful treatment with antiretroviral therapy (ART). This means that people living with HIV who are treated before significant immunodeficiency are expected, with life-long treatment, to live a normal lifespan. ART may result in reductions in bone mineralisation and kidney function, although this remains poorly studied in women. 

This trial will examine the effects of switching ART regimen on bone mineralisation and kidney function. Preservation of bone mineral density is particularly relevant in the study population of women over 40. 

Participants will be randomised to switch to Triumeq (abacavir/lamivudine/dolutegravir), or continue their existing triple therapy (consisting of tenofovir/emtricitabine or lamivudine, plus an NNRTI [efavirenz, nevirapine, etravirine or rilpivirine]). 

The primary outcome will be the change from baseline in total hip bone mineral density at week 48, in each arm.

Links to other research

Other research from the UCL Centre for Clinical Research in Infection and Sexual Health

Other research from IGH on Randomised Controlled TrialsHIV and Women's Health

Other research from IGH in the UK